SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 0.910+4.6%Feb 6 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote (164)12/2/1997 3:17:00 PM
From: Don W Stone  Read Replies (1) of 507
 
Forbes, December 15, 1997. (ref. Pg.254) "SmithKline's promising vaccines"
It is a brief write up on SKB's vaccine hopes from one mans perspective.
I'll quote the one and only statement that is related to NVX : "The company's latest DNA-derived vaccine is an updated version of the classic childhood diptheria-tetanus-whooping cough inoculation."

We'll talking here about the SKB vaccine that was recently approved, for the 1st three shots only in infants. The adverse events were so severe by the 4th shot that they, SKB never finished the study let alone go for the 5th shot.
As I said in an earlier post if anyone wants to seriously know more about how they, SKB, are doing with their lastest "DNA-derived"?????????? DTaP vaccine they should contact the Swedes.
But than too, whose DTaP vaccine do you use for the booster if you use the SKB vaccine for shots 1, 2 & 3?
I don't mean to knock SKB as a drug company.
The Point I am trying to make is: 1) that right now NVX's competition with DTaP will come from Lederle and Connaught in the U.S.and not from SKB, 2) this article did not disclose anything new that would change the situation and 3) If you unloaded NVX today because of this article you goofed. :-}
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext